SOMAÍ: Setting New Standards in Medicinal Cannabis

Cannabis is a plant documented since ancient times as a provider of cloth, food and medicine, and has been found to have countless therapeutic usages. More than 100 cannabinoids have been found in the cannabis plant and it has been described as relieving symptoms of many illnesses, such as neurological illnesses for which therapy is still lacking promising medication that provides an improved quality of life for patients suffering from these ailments. Therefore, Cannabis is chemically a “treasure trove” of novel compounds to be studied and brought to the medical market.

SOMAÍ Pharmaceuticals works at the forefront of research, setting new standards for therapeutic innovation to provide relief for debilitating chronic conditions. We believe that all patients suffering from uncontrolled conditions should have access to effective medical cannabis products. At SOMAÍ Pharmaceuticals we pride ourselves in using the highest quality raw materials in order to formulate novel medications, with high bioavailability targeting the endocannabinoid system to provide relief for specific conditions.

To better understand the full capabilities of cannabis as well as the composition of its biomass, the goal of the present work was to characterize the purified extract as well as the residues obtained from SOMAÍ production. We will present the cannabinoids and non-cannabinoids (eg. phenolic compounds and waxes) extracted and retained in the biomass leftover from the DEVEX ethanolic process. The cannabinoids and other phytoproducts identification and quantification (HPLC and GC techniques) will be presented for the future promising SOMAÍ products that will be integrated into new therapies.

Publication History

Article published online:
16 November 2023